PF-07260437(Pfizer)

N/A

Report date: 2026/03/19 17:22:24

Base Information

Drug NamePF-07260437(Pfizer)

Drug Alias NameB7-H4PF-07260437

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionV-set domain-containing T-cell activation inhibitor 1 inhibitorsAnti-CD3

TargetsV-set domain-containing T-cell activation inhibitor 1T cell surface glycoprotein CD3

Therapy Area/IndicationsEndometrial NeoplasmsOvarian NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto Rico

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsEndometrial NeoplasmsOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A